A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
Conditions
Lung
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
- Trial withAstra Zeneca
- Start Date02/24/2020
- End Date11/10/2022
For more information about this study, contact:
Kira Fitzsimons Pavlik
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Andrea Brennan
- Andrea Martelli
- Anne Chiang, MD, PhD
- David Witt, MD
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jaykumar Thumar, MBBS, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathryn Medow, APRN
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Roy S. Herbst, MD, PhD
- Scott Gettinger, MD
- Last Updated10/21/2020
- Study HIC#2000025651